Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Fusion IP plc    FIP   GB00B05L5X50

SummaryQuotesNewsCalendarCompanyFinancials 
News SummaryMost relevantAll newsSector news 

Fusion IP plc : Simcyp develops virtual laboratory mouse for use in cancer and toxicology research

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/19/2012 | 11:07am CET

Sheffield, UK. 18th January 2012. Simcyp Limited , the leader in modelling and simulation of drug-drug interactions in virtual human populations, today announces it has extended its animal models to include a virtual mouse.

Laboratory mice are used extensively in the development of new anti-cancer drugs as well as toxicological studies involving agrochemicals.  This research often involves using mice which have been genetically modified in order to investigate the role that drug metabolising enzymes and transporters play in the accumlation of drugs in the whole animal or in specific tissues.  The Simcyp Mouse provides a virtual environment for evaluating drug disposition which will replace the need for some live animal testing in normal as well as transgenic mice, thus reducing and refining preclinical investigation.

The Simcyp Simulators are mathmatical models linking numerous physiological, genetic and biochemical databases with drug-specific data to produce "real-life" predictions to help optimise drug development.  The ability to create virtual transgenic mice by adding (knocking-in) or deleting (knocking-out) certain genes is a unique feature of this model.

Dr Steve Toon, Executive Director at Simcyp, commented:  "The Simcyp Mouse Simulator is a valuable addition to our portfolio of virtual animal models.  Simcyp Mouse will be an incredibly useful tool for scientists and clinicians developing new anti-cancer drugs helping reduce cost, accelerate development timelines and reduce animal testing.  I am proud that Simcyp is able to make its own contribution to the advancement of cancer research."

Members of the Simcyp Consortium of leading pharmaceutical and biotechnology companies have automatic access to all of Simcyp's preclinical models with the latest release of the Simcyp Population-based Simulator.  Licenses for Simcyp Animal can now also be granted to companies outside of the Consortium including contract research organisations.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on FUSION IP PLC
2014 FUSION IP : Court Confirmation of Capital Reduction and Effective Date
2014 FUSION IP : Exercise of Options
2014 FUSION IP : Rule 2.10 Announcement
2014 FUSION IP PLC : Rule 2.0 Announcement
2014 FUSION IP PLC : Results of the Court Meeting and General Meeting
2014 FUSION IP PLC : Further announcement 24th February – Scheme Document
2014 FUSION IP PLC : Fusion portfolio company Asalus awarded CE mark for Ultravision
2013 FUSION IP PLC : Phase Focus strengthens Board with New Chairman and Directors
2013 FUSION IP PLC : Absynth Biologics Limited secures £850,000 funding to develop it..
2013 FUSION IP PLC : Fusion portfolio company MedaPhor expands sales into China throu..
More news
Sector news : Venture Capital
12/02DJMorgan Stanley Toughens Pay Hurdles for Brokers
12/02 Trump creates business advisory council stacked with CEOs
12/01 CREDIT SUISSE : Swiss spin-off faces same capital rules as group
11/29DJAMP : Makes Changes to Senior Leadership
11/28 Britain's JD Sports buys Go Outdoors for 112 million pounds
More sector news : Venture Capital
Advertisement
Income Statement Evolution
More Financials
Managers
NameTitle
Peter Leonard Grant Executive Director & Operations Director
David Michael Davies Non-Executive Director
David Graham Baynes Executive Director
Robert Rabone Non-Executive Director
David John Catton Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
FUSION IP PLC0.00%0
UBS GROUP AG0.00%60 621
BLACKROCK, INC.9.06%60 186
GOLDMAN SACHS BDC INC21.84%55 974
BANK OF NEW YORK MELLO..15.04%50 382
STATE STREET CORP18.75%30 257
More Results